Resultados de Búsqueda

NICE

National Institute for Health and Clinical Excellence (NICE)

Screening for malnutrition and the risk of malnutrition should be carried out by healthcare professionals with appropriate skills and training. All hospital inpatients on admission and all outpatients at their first clinic appointment should be screened. Screening should be repeated weekly for inpatients and when there is clinical concern for outpatients. Hospital departments who identify groups of patients with low risk of malnutrition may opt out of screening these groups. Opt-out decisions ...

NICE

National Institute for Health and Clinical Excellence (NICE)

All healthcare professionals who are directly involved in patient care should receive education and training, relevant to their post, on the importance of providing adequate nutrition. Education and training should cover: nutritional needs and indications for nutrition support options for nutrition support (oral, enteral and parenteral) ethical and legal concepts potential risks and benefits when and where to seek expert advice.

NICE

National Institute for Health and Clinical Excellence (NICE)

1.1 Ustekinumab is recommended, within its marketing authorisation, as an option for treating moderately to severely active Crohn's disease, that is, for adults who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF‑alpha inhibitor or have medical contraindications to such therapies. 1.2 The choice of treatment between ustekinumab or another biological therapy should be made on an individual basis after discussion between the ...

Too Much Medicine - theBMJ [Demasiada Medicina-TheBMJ]

Mayor S. BMJ 2017;358:j4120

The controversy about PSA based screening should no longer be whether it can do good but whether we can change our behaviour so that it does more good than harm. For further information please visit the website of the initiative (link below)

Too Much Medicine - theBMJ [Demasiada Medicina-TheBMJ]

Mayor S. BMJ

Treating older people who have moderate hyperlipidaemia and hypertension with statins for primary prevention of cardiovascular disease does not reduce mortality or coronary heart disease events, results from a post-hoc analysis of a large randomised trial have shown. Therefore, treatment recommendations should be individualised for this population.